Innovent's Mazdutide 9mg application accepted for obesity treatment in China

Innovent Biologics announced that China's NMPA has accepted the supplementary application for mazdutide 9mg, a GCG/GLP-1 dual receptor agonist, for long-term weight management in adults with moderate to severe obesity. This application follows encouraging results from the Phase 3 GLORY-2 clinical study.

The GLORY-2 study demonstrated significant efficacy, with participants in the mazdutide 9mg group achieving a mean weight reduction of 18.55% at week 60, compared to 3.02% in the placebo group. Notably, 44.0% of participants achieved a weight reduction of 20% or more, alongside improvements in liver fat content (71.9% reduction), blood pressure, blood lipids, and serum uric acid.

Mazdutide 9mg also exhibited a favorable safety profile with no new safety signals. The company's strategic portfolio now includes 3mg-6mg-9mg dosages targeting severely obese populations.